Filament Health revenue slides 94% as cash reserves dwindle
The FDA and Health Canada both cleared Phase II trials for Filament’s flagship psilocybin drug candidate.
The post Filament Health revenue slides 94% as cash reserves dwindle appeared first on Green Market Report.
